Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.54 |
| ▸ | CDK2 | P24941 | 7/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103846 | 0.81 | RAB9A (0.59) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL473446 | 0.78 | RAB9A (0.55) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL10104143 | 0.76 | RAB9A (0.52) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL473574 | 0.76 | MAPK8 (0.56) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL678640 | 0.75 | RAB9A (1.00) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL30355239 | 0.75 | RAB9A (1.00) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL473534 | 0.74 | MKNK2 (0.56) | RAB9ACYP2C9RPS6KA5SMN1; SMN2TSHR | |
| SCHEMBL19100862 | 0.74 | RPS6KA5 (0.58) | RAB9AMAPK8MAPK9CDK2MAPK10 | |
| SCHEMBL30459875 | 0.73 | MKNK1 (0.51) | MAPK8MAPK9MAPK10RPS6KA5CDK1 | |
| SCHEMBL17683140 | 0.73 | MKNK1 (0.51) | MAPK8MAPK9MAPK10RPS6KA5CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2021-12-21 | — | — | US | disclosed |
| EP-3885344-A2 | PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101511359-A | Benzotriazole kinase modulators | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | RAB9A 1035/4885MAPK8 119/4885MAPK9 225/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | RAB9A 1035/4885MAPK8 119/4885MAPK9 225/4885 |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, TP53 | RAB9A 954/4885MAPK8 167/4885MAPK9 215/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | RAB9A 935/4885MAPK8 158/4885MAPK9 218/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | RAB9A 1035/4885MAPK8 119/4885MAPK9 225/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | RAB9A 3749/4885MAPK8 61/4885MAPK9 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.